BlackRock Health Sciences Term Trust (BMEZ) Stock
1 member of Congress disclosed 1 trade in BMEZ since 2020: 1 purchase and 0 sales, most recently John Hoeven (purchase, Jan 29, 2020). 2 of the hedge funds AlphaScala tracks reported BMEZ in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $428.0K.
Which members of Congress traded BlackRock Health Sciences Term Trust (BMEZ)?
Most recent: John Hoeven (purchase, Jan 29, 2020); records start Jan 29, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| John Hoeven R-ND · Senate | 2020-01-29 | purchase | $100k – $250k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all BMEZ political trades →Which hedge funds own BMEZ?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 28K | $428.0K | -57% |
| Citadel Ken Griffin | 15K | $237.1K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →BMEZ price chart
Powered by TradingViewWhat does BlackRock Health Sciences Term Trust do?
BlackRock Health Sciences Trust II is a closed-end fund designed to deliver total return and income through a combination of current income, current gains, and long-term capital appreciation. The trust primarily invests at least 80% of its assets in equity securities of companies principally engaged in the health sciences sector, including biotechnology, pharmaceuticals, medical devices, and healthcare services. Additionally, it employs an option writing strategy on a portion of its assets to generate current gains from option premiums, aiming to enhance risk-adjusted returns and provide a consistent income stream to investors. The fund is actively managed by a team of experienced portfolio managers and typically maintains a diversified portfolio with holdings in leading global health sciences companies. BlackRock Health Sciences Trust II plays a notable role in the market by offering targeted exposure to the innovation-driven health sector, balancing opportunities for capital growth with regular income distributions, and utilizing risk management through options strategies.